VTV250516C140000
- 21.70
- 0.000.00%
Vanguard Value ETF Newsroom
Wall Street Winners: 10 Buy-rated Stocks Soaring 10%+ in 2025
SA Analyst Downgrades: T, DOW, SMCI, UNH
About 75% of the Names That Reported Earnings This Week Delivered EPS Wins: Earnings Scorecard
SA Analyst Upgrades: GOOG, NVDA, INTC, XOM, MU, ADBE, NEE, NXPI, WU
Earnings Call Summary | AbbVie(ABBV.US) Q1 2025 Earnings Conference
Morgan Stanley Maintains Overweight on Procter & Gamble, Lowers Price Target to $180
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Amazon Sellers Hike Prices On Essentials As Trump China Tariffs Squeeze Margins
Procter & Gamble Analysts Lower Their Forecasts Following Q3 Results
Check Out What Whales Are Doing With UNH
UnitedHealth Group Shares Are Trading Lower After Barclays Cut Its Price Target on the Stock From $560 to $513.
Citigroup Maintains Buy on Procter & Gamble, Lowers Price Target to $181
4 Stocks to Watch on Friday: GILD, ABBV, CL and SLB
Procter & Gamble Analyst Ratings
AbbVie Spikes as Q1 Beat Prompts Guidance Raise
AbbVie Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Adjusted EPS Guidance.
Earnings Snapshot: AbbVie Tops Q1 Estimates Even as Humira Sales Lag, Profit Outlook Beats
AbbVie Non-GAAP EPS of $2.46 Beats by $0.06, Revenue of $13.34B Beats by $420M
Earnings Scheduled For April 25, 2025
The economic uncertainty is too great, and Americans are afraid to buy houses now.
High interest rates continue to stifle market demand, coupled with tariffs increasing economic uncertainty, leading to a collapse in USA home sales in March, reaching the worst level since the financial crisis.